The statin group experienced an average LDL-C reduction of 37.9%, according to the results of the single-center, prospective, randomized, single-blind SPORT study (Supplements, Placebo, or Rosuvastatin), while those who took dietary supplements experienced LDL-C changes similar to those in the placebo group. Additionally, rosuvastatin-treated patients experienced average decreases in triglycerides of 19% and total cholesterol of 24%. For any of the supplements, there were no differences in either total cholesterol or triglycerides when compared to placebo.

The 8-week treatment with mindfulness-based stress reduction was a well-tolerated treatment option with comparable effectiveness to a first-line medication for patients with anxiety disorders in this randomized clinical trial of 276 adults with anxiety disorders.

Relapsing MS treatment remains difficult, and new therapeutic targets have been investigated. S1P, a bioactive lysophospholipid signaling molecule present in several organs, including the central nervous system, is one such target. S1P plays a role in a variety of physiologic and pathophysiologic processes. S1P levels have been linked to disease progression in the brain parenchyma and cerebrospinal fluid of MS patients. There are 5 recognized S1PR subtypes, and depending on the receptor being targeted, their expression patterns and outcomes change. S1PRMs are a more recent class of RMS treatments, and the FDA has currently approved 4 of these treatments: fingolimod, siponimod, ozanimod, and ponesimod.

A neurologist’s funeral took place this year. His life, experiences, role in their development, and work as a doctor and community member were all discussed by family members. A person’s life is woven together like a tapestry by their experiences, which include success and failure, relationships with others, and other woven connections to the essential experience of life.

Two JAMA papers suggest that more side effects correlates with higher levels of anti-spike antibodies. But anti-spike antibodies develop even in individuals who experienced evident reaction, with the possible exception of those on immunosuppressant regimens.

In a high-risk population, vaccination was better than prior infection, with incremental increase in protection with additional vaccination doses. Prior infection in unvaccinated individuals ranged from 16% to 49% vs omicron infection Versus unvaccinated, previously uninfected individuals, vaccine effectiveness at preventing omicron infection ranged from 19% to 83% with 2 doses and 41% to 88% with 3 doses Three vaccine doses offered significantly more protection than two doses, including among previously infected persons